Abstract: A method for making a biomaterial comprising providing at least one polypeptide fraction chymotryptically isolated and extracted from fibroin, and adding the at least one extracted polypeptide fraction to a hydrogel precursor before gelling, wherein the at least one isolated and extracted polypeptide fraction is selected from a soluble fraction Cs, and a precipitated fraction Cp. A biomaterial comprising at least one of the isolated and extracted polypeptide fractions incorporated in a hydrogel or a hydrogel precursor. Use of the biomaterial for constructing, regenerating, repairing, replacing or augmenting soft or hard tissue; as an in vitro or in vivo construct; as a coating material; or as a cell, molecule or particle delivery medium. Use of the isolated and extracted polypeptide fraction Cs for promoting osteoinduction, osteoconduction or osteogenesis. Use of the isolated and extracted polypeptide fraction Cp for enhancing a mechanical compressive modulus of a material into which it is incorporated.

Abstract: The present invention relates to methods for the treatment of a disease or condition associated with lipid imbalance, comprising (a) decreasing arachidonic acid (AA) levels, (b) increasing docosahexaenoic acid (DHA) levels, (c) increasing DHA/AA ratio or (d) any combination of (a)-(c) in a subject using fenretinide. The invention also relates to diagnostic and screening methods based on the determination of lipid levels.

Abstract: Fluorescence based sensing systems and methods that exploit xerogels are provided. Embodiments of the invention encompass a sensing system that includes: an optical excitation source emitting over a first predetermined wavelength range and capable of analog modulation over a predetermined frequency range; a sensor including a gel substrate incorporating within its matrix a receptor for molecular recognition of an analyte and a luminophore for signaling a recognition event relating to the analyte, the luminophore emitting an optical signal over a second predetermined wavelength range; a detection circuit including an optical detector for receiving the optical signal emitted by the luminophore and generating a photocurrent in dependence thereof; an excitation circuit that generates an analog signal for modulating the optical excitation source in dependence upon a digital control; and a read circuit for receiving the photocurrent and generating a digital output.

Abstract: Low-Density Parity-Check (LDPC) codes offer error correction at rates approaching the link channel capacity and reliable and efficient information transfer over bandwidth or return-channel constrained links with data-corrupting noise present. They also offer performance approaching channel capacity exponentially fast in terms of the code length, linear processing complexity, and parallelism that scales with code length. They also offer challenges relating to decoding complexity and error floors limiting achievable bit-error rates.

Abstract: Amongst the candidates for very high efficiency solid state light sources and full solar spectrum solar cells are devices based upon InGaN nanowires. Additionally these nanowires typically require heterostructures, quantum dots, etc which all place requirements for these structures to be grown with relatively few defects and in a controllable reproducible manner. Additionally flexibility according to the device design requires that the nanowire at the substrate may be either InN or GaN. According to the invention a method of growing relatively defect free nanowires and associated structures for group IIIA-nitrides is presented without the requirement for foreign metal catalysts and overcoming the non-uniform growth of prior art non-catalyst growth techniques. According to other embodiments of the invention self-organizing dot-within-a-dot nanowire and dot-within-a-dot-within-a-well nanowire structures are presented.

Abstract: A method for diagnosing the presence of hereditary spastic paraplegia (HSP) or predicting the risk of developing HSP in a human subject, comprising detecting the presence or absence of a defect in a gene encoding a polypeptide comprising the sequence of FIG. 9 (SEQ ID NO: 19), in a nucleic acid sample of the subject, whereby the detection of the defect is indicative that the subject has or is at risk of developing HSP.

Abstract: Atomic Force Microscopes (AFMs) allow forces within systems under observation to be probed from the piconewton forces of a single covalent bond to the forces exerted by cells in the micronewton range. The pendulum geometry prevents the snap-to-contact problem afflicting soft cantilevers in AFMs which enable attonewton force sensitivity. However, the microscopic length scale studies of cellular/subcellular forces parallel to the imaging plane of an optical microscope requires high sensitivity force measurements at high sampling frequencies despite the difficulties of implementing the pendulum geometry from constraints imposed by the focused incoming/outgoing light interfering with the sample surface. Additionally measurement systems for biological tissue samples in vitro must satisfy complex physical constraints to provide access to the vertical cantilever.

Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.

Abstract: A method of providing microelectromechanical structures (MEMS) that are compatible with silicon CMOS electronics is provided. The method providing for processes and manufacturing sequences limiting the maximum exposure of an integrated circuit upon which the MEMS is manufactured to below 350° C., and potentially to below 250° C., thereby allowing direct manufacturing of the MEMS devices onto electronics, such as Si CMOS circuits. The method further providing for the provisioning of MEMS devices with multiple non-conductive structural layers such as silicon carbide separated with small lateral gaps. Such silicon carbide structures offering enhanced material properties, increased environmental and chemical resilience whilst also allowing novel designs to be implemented taking advantage of the non-conductive material of the structural layer.

Abstract: Hybrid molecules comprising a retinoic acid receptor agonist moiety and a histone deacetylase inhibitor (HDAC) moiety are disclosed. Hybrid molecule 3 (6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-hydroxamic acid) was proven to posses HDAC activity while maintaining RAR agonist activity. Hybrid molecule 3 and pharmaceutical compositions thereof can be used in the treatment of breast cancer, leukemia, non-small cell lung cancer, colon cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and cancer of the CNS.

Abstract: Advances in a variety of fields such as micromachined silicon in conjunction with MEMS and other devices and attaching biosensors to electrode structures have allowed discrete or continuous monitoring devices to be implemented for biological systems, chemical processes, environmental monitoring etc. However, such devices are typically analysed within controlled laboratory environments due to bulky and large electrochemical impedance measurement systems. In many situations deployment in field, clinic, point-of-care, or consumer scenarios would be beneficial. Accordingly it an intention of the invention to provide a measurement system which offers potential for low cost implementations via multiple technologies to address the different cost targets of these applications as well as number of measurement cells within each. Additionally embodiments of the invention are self-calibrating and self-referencing allowing their use in such scenarios absent highly trained technicians.

Abstract: The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise ?-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.

Abstract: A method and an apparatus are provided for providing a tunable substrate integrated waveguide (SIW) for which a parameter of at least some element or portion thereof may be altered or varied to alter the propagation of a signal propagating through the SIW thereby achieving a tunable SIW. In some embodiments a plurality of capacitively variably loaded transverse slots achieve the tunability for the SIW.

Abstract: This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof; wherein R1 to R4, R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.

Abstract: Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, pro-drugs, precursors thereof, and/or salts thereof, are described.

Abstract: Methods, reagents and kits are described for the diagnosis of a female reproductive condition such as reproductive wastage, based on the detection of an alteration in a NLRP7-encoding nucleic acid or a NLRP7 polypeptide, relative to a corresponding wild-type NLRP7-encoding nucleic acid or NLRP7 polypeptide.

Abstract: A process for treating a protein before hydrolytic digestion, the process comprising exposing the protein to at least one cycle of microwave irradiation to produce a microwave treated protein containing one or more bioactive peptides. Further hydrolyzing the microwave treated protein to release at least one of the one or more bioactive peptides. A pharmaceutical composition, supplement and food product including the microwave treated protein or the one or more released bioactive peptides.

Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.

Abstract: Polymers and copolymers containing 1H-benzo[d]imidazol-2(3H)-one units have been synthesized under conditions generally used for the synthesis of poly(aryl ether)s. 1H- benzo[d]imidazol-2(3H)-one behaves like a biphenol in the polymerization reaction. The soluble homopolymer has a very high glass transition temperature (348° C.), good thermal stability, and forms flexible transparent films. Because of the low molecular weight (134.14) of the benzoimidazolone monomer in the copolymer formed with 4,4?-biphenol that contains 30 mole % of the benzimidazolone unit, only 8.9 weight % is required to raise the Tg of the poly(arlyl ether)sulfone from 220° C. to 269° C.

Abstract: Peptides comprising a cadherin cell adhesion recognition (CAR) sequence, and compositions comprising such peptides, are provided. Methods of using such peptides for modulating cadherin-mediated processes in a variety of therapeutic contexts are also provided. Methods are also provided for identifying compounds that are capable of modulating cadherin-mediated processes.